Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas B Vischedyk

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nature Communications|June 4, 2014
Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferasesJoël P Charles, Jeannette Fuchs, Mirjam Hefter, et al.
Autophagy|July 13, 2023
Deciphering the mitophagy receptor network identifies a crucial role for OPTN (optineurin) in acute myeloid leukemiaLaura M Meyer, Sebastian E Koschade, Jonas B Vischedyk, et al.
Nature Chemical Biology|November 24, 2015
CRISPR-Cas9-based target validation for p53-reactivating model compoundsMichael Wanzel, Jonas B Vischedyk, Miriam P Gittler, et al.
Cancers|December 10, 2021
Metabolic Rewiring Is Essential for AML Cell Survival to Overcome Autophagy Inhibition by Loss of ATG3Fatima Baker, Ibrahim H Polat, Khalil Abou-El-Ardat, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nature Communications|June 4, 2014
Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferasesJoël P Charles, Jeannette Fuchs, Mirjam Hefter, et al.
Autophagy|July 13, 2023
Deciphering the mitophagy receptor network identifies a crucial role for OPTN (optineurin) in acute myeloid leukemiaLaura M Meyer, Sebastian E Koschade, Jonas B Vischedyk, et al.
Nature Chemical Biology|November 24, 2015
CRISPR-Cas9-based target validation for p53-reactivating model compoundsMichael Wanzel, Jonas B Vischedyk, Miriam P Gittler, et al.
Cancers|December 10, 2021
Metabolic Rewiring Is Essential for AML Cell Survival to Overcome Autophagy Inhibition by Loss of ATG3Fatima Baker, Ibrahim H Polat, Khalil Abou-El-Ardat, et al.
European Journal of Haematology|July 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapyFabian Acker, Jörg Chromik, Emily Tiedjen, et al.
Leukemia & Lymphoma|March 22, 2026
Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphomaClara Walter, Michael C Burger, Kai Siebenbrodt, et al.
Pageof 1